Jan 28, 2020, 08:45
Carbiotix (publ) ("Carbiotix") announces today that Dr. Jan Marsal will join the company"s Advisory Board as the company ramps up pre-clinical activities in the areas of IBD, hyperammonemia, and neuroinflammation. Dr. Marsal is considered a leading expert in the area of IBD, as well as the link between gut health and other disease areas. This addition to the Advisory Board will strengthen Carbiotix"s ability to leverage its technology platform and bring gut health-related products and services to the market.
Dr. Marsal is currently an Associate Professor at the Department of Immunology (EMV) and Medicine (IKVL) at Lund University, and an MD in Internal Medicine and Gastroenterology/Hepatology at Skåne University Hospital. His main lines of research include investigating the pathobiology and immunology of IBD, exploring tools for optimising the clinical management of IBD, research projects regarding systemic inflammatory diseases, and exploring the management of immunological side-effects from Immune Checkpoint Inhibitor (ICPI) cancer therapeutics.
Kristofer Cook, CEO for Carbiotix, comments
"We are extremely happy to welcome Dr. Marsal to our Advisory Board and look forward to working closely with him as we ramp up our pre-clinical and clinical activities going forward. Dr. Marsal"s advice will play a key role in shaping our clinical plans and market strategy. Moreover, Dr. Marsal"s network in the pharmaceutical industry should create opportunities to garner interest from key industry players."
Dr. Peter Falck, CSO for Carbiotix, comments
"Dr. Marsal brings a wealth of practical knowledge in the IBD area, as well as other disease areas linked to gut health. His background and research interests fit perfectly with Carbiotix"s current service portfolio and product development plans, thus setting the stage for a very productive collaborative relationship that will be mutually beneficial. I look forward to interacting with Dr. Marsal in the months and years to come."
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company"s contact person set out below on 28 January 2020.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.